Pioglitazone, a selective agonist of the peroxisome proliferator-activated receptor gamma (PPARγ), is recommended to treat MASH and/or fibrosis in individuals with T2DM,295,298,308 because most studies comparing pioglitazone and placebo have shown benefits in inflammation and histological changes.312 However, there was no sub-analysis regarding sex in most of them. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.